A RETROSPECTIVE, CROSS-SECTIONAL, OBSERVATIONAL STUDY COMPARING THE EFFICACY OF VARIOUS COVID-19 TREATMENT PROTOCOLS
Purpose and Background: The goal of this study is to examine the efficacy of various medications that are recommended for the treatment of patients in India who are suffering from mild-to-severe cases of corona virus disease 2019 (COVID-19). Methods: In study carried out a retrospective, cross-secti...
Gespeichert in:
Veröffentlicht in: | NeuroQuantology 2022-01, Vol.20 (9), p.5453 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose and Background: The goal of this study is to examine the efficacy of various medications that are recommended for the treatment of patients in India who are suffering from mild-to-severe cases of corona virus disease 2019 (COVID-19). Methods: In study carried out a retrospective, cross-sectional, observational and descriptive study. Patients diagnosed with COVID-19 ranging from mild, moderate and severe were given as part of this treatment. The primary objectives are to compare the categorical treatment protocols for COVID-19 (as per NIH Treatment Guidelines) infected mild, moderate and severe patients. To evaluate the efficacy of the drugs on the basis of at the time of discharge improvement in SPO2, RR, D-Dimer, PCT, CRP and Ferritin Values. Results: A total of 266 patients included in this study mild to severe COVID 19 infection led to significant improvement in SPO2, Respiratory rate (RR), D-Dimer, Procalcitonin (PCT), C-Reactive Protein (CRP) and Ferritin level. Conclusion: Adult patients with mild, moderate and severe COVID- 19 infection, when treated with different drug combination, were more likely to improve in terms of inflammatory markers and disease severity markers and were more likely to have a better clinical profile at the end of the treatment period |
---|---|
ISSN: | 1303-5150 |
DOI: | 10.14704/nq.2022.20.9.NQ44637 |